West China Lecheng Hospital
Strategic extension of West China Hospital of Sichuan University in Lecheng · Leader in gene therapy and cardiovascular stem cell therapy in the Lecheng Pilot Zone
Hospital Overview
West China Lecheng Hospital (Hainan Hankong Lecheng Hospital) is the strategic extension of China's top hospital — West China Hospital of Sichuan University — in the Boao Lecheng Pilot Zone. West China Hospital has ranked #1 in China's comprehensive hospital rankings for many consecutive years; the Lecheng hospital inherits the West China brand and academic strength, fully leveraging Lecheng's 'National 9 Articles' franchise policy.
The hospital focuses on three frontier directions: gene therapy, cardiovascular stem cell therapy, and tumor immunology. Among them, AAV gene therapy for Hemophilia A — at ¥680,000 per dose — is Lecheng's highest-priced single gene therapy project, representing the highest level of clinical translation of gene therapy in China.
Key Facts
All Approved Biomedical Technology Projects
Gene Therapy (Flagship · Lecheng's Highest Unit Price)
West China Lecheng is Lecheng's core gene therapy platform; AAV gene therapy for Hemophilia A represents the highest level in this field in China
Hemophilia A Adeno-Associated Virus (AAV) Gene Therapy
For Hemophilia A caused by congenital coagulation factor VIII deficiency. An AAV vector delivers the normal FVIII gene into liver cells so patients continuously produce their own clotting factor, enabling one-time treatment, long-term remission, or even lifelong cure — freeing patients from lifelong regular factor infusions. Currently Lecheng's highest-priced single gene therapy project and a benchmark for clinical translation of gene therapy in China.
Cardiovascular & Liver Stem Cell Therapy
Human Umbilical Cord-Derived MSC Therapy for Heart Failure
For chronic heart failure patients with LVEF ≤ 40%, NYHA class II-IV. Umbilical cord MSCs promote myocardial repair, suppress fibrosis, and stimulate angiogenesis through paracrine effects, improving cardiac function.
Human Umbilical Cord MSC (VUM02 Injection) for Liver Cirrhosis
For compensated and decompensated cirrhosis. Umbilical cord MSCs improve liver function and slow progression through three mechanisms: anti-fibrosis, immune regulation, and promotion of hepatocyte regeneration. Compared with liver transplant: less invasive, lower cost, no donor wait.
Allogeneic Endothelial Progenitor Cells (EPCs) for Critical Limb Ischemia
For critical lower-limb ischemia caused by diabetic foot, arteriosclerosis obliterans, etc. After infusion, allogeneic EPCs home to ischemic sites, promote new blood vessel formation and improve limb perfusion, offering a limb-salvage option for patients facing amputation.
Tumor Immune Cell Therapy
Personalized DC Vaccine Therapy for Malignant Tumors
The patient's own dendritic cells (DCs) are collected, loaded in vitro with tumor-specific antigens, and reinfused to activate the patient's T cells for precise tumor killing. Very broad cancer coverage: liver, lung, melanoma, breast, urothelial, pancreatic, GI tumors (colorectal, esophageal), gynecologic tumors (ovarian, cervical), and head & neck tumors (nasopharyngeal).
Stem Cell Therapy for Bone & Joint Diseases
Umbilical Cord MSC for Knee Osteoarthritis
Intra-articular injection of umbilical cord MSCs suppresses synovial inflammation and promotes cartilage repair and regeneration. Minimally invasive, no hospitalization required.
Human Umbilical Cord MSC for Rheumatoid Arthritis
For rheumatoid arthritis with poor response to conventional DMARDs. Umbilical cord MSCs have powerful immunomodulatory function, suppressing abnormally activated T/B cells and synovial inflammation, relieving joint swelling, pain, and morning stiffness.
Why Choose West China Lecheng Hospital
West China — #1 in China
West China Hospital of Sichuan University has ranked #1 nationwide for many consecutive years. The Lecheng hospital is West China's only extension in the medical special zone, with clinical quality backed by a top brand.
Gene Therapy Benchmark
Hemophilia A AAV gene therapy is Lecheng's highest-priced and most technically complex single gene therapy project, representing the highest level of clinical translation of gene therapy in China.
Broad-Spectrum DC Vaccine
The DC vaccine covers 9 major categories of solid tumors including liver, lung, and breast cancer — Lecheng's cell immunotherapy project with the widest cancer coverage.
Want to consult West China Lecheng Hospital's advanced treatments?
Our medical advisors will assess the suitability of gene therapy, stem cell therapy, or DC vaccine based on your condition.
Book a Consultation